lanzx014
Sickle Cell Disease (SCD) affects approximately 100,000 people in the United States, stemming from an abnormal protein in red blood cells that disrupts oxygen transport throughout the body. Due to the disease's complexity, advancements in care and treatment have been slow. However, research facilities like the University of Minnesota are at the forefront of bridging this gap, working to develop innovative curative therapies, comprehensive care regimens, and effective pharmaceutical drugs to improve outcomes for those affected by SCD.